Abstract
Background
Although gait speed typically declines with age, some individuals manage to maintain higher walking speeds well into older age. To better understand healthy longevity, we propose a novel exceptional aging phenotype of super movers, individuals 80 years or older with walking speeds comparable to individuals 3 decades younger.
Methods
We conducted a retrospective cohort study to examine the epidemiology and determinants of super mover status as well as mortality, biological aging and gait speed trajectories of super movers compared to age peers identified from 15 aging cohort studies across 24 countries.
Results
In a pooled cohort of data from multicountry population-based surveys, prevalence of super movers ranged from 4.9% to 11.1% in individuals 80 and older, with an average overall prevalence of 7.3%. Compared to age peers, super movers exhibited lower disease prevalence, healthier lifestyles and had lower mortality rates (hazard ratios: 0.38, 95% CI: 0.09–0.66). In 2 smaller samples with gait and biological aging data and longitudinal gait assessments, compared to age-matched peers, super movers had younger biological age and showed faster gait speed from their seventh to tenth decades, respectively.
Conclusions
Super movers are an exceptional aging phenotype enriched with unique biological and clinical profiles that can provide valuable insights into healthy longevity.
Keywords: Cognition, Epidemiology, Gait, Longevity, Mortality, Successful aging
Gait speed is a vital sign reflecting the integration of health, disease, fitness, and emotional state in aging (1). Faster gait is a robust indicator of survival (2). Conversely, slow gait predicts adverse outcomes such as falls, disability, and dementia (1). While gait speed, on the average, declines with advancing age (3), some rare individuals maintain higher gait speeds as they age. We present the novel concept of “super movers”: individuals aged 80 years and older without dementia and disability with gait speed of adults 30 years younger. We hypothesize that this exceptional aging phenotype is enriched with unique biological, clinical, and behavioral profiles that help these individuals maintain superior (above average) gait speed into their ninth decade. Studies of extremely successful aging phenotypes such as longevity (centenarians (4,5)) and cognition (super agers (6)) have yielded valuable insights into healthy and pathological aging. Hence, studying super movers can provide a unique window into protective mechanisms enabling healthy longevity.
To describe the epidemiology and determinants of the super mover phenotype, we identified 6 259 individuals aged 80 and older from 29 692 individuals aged 65 and older across 13 established aging studies in 24 countries. We assessed the clinical relevance of this phenotype by evaluating risk of mortality among super movers versus nonsuper movers—in cohorts with longitudinal follow-up. Next, in 2 cohorts of smaller samples, we compared biological markers as well as gait speed decline trajectories between super movers and nonsuper movers. We hypothesized that super movers would exhibit younger biological age, as measured by epigenetic aging clocks (7), and would maintain superior gait speed throughout follow-up compared to age-matched peers.
Method
Experimental Design
To examine the epidemiology and clinical profiles of super movers, we used individual data from participants in 13 established aging studies with comparable gait and clinical assessments representing 24 countries.
the HRS International Network of Studies (HRS-INS) United States HRS, United Kingdom (English Longitudinal Study of Ageing [ELSA]), China (Chinese Health and Retirement Longitudinal Study [CHARLS]) (8), 14 European countries and Israel (Survey of Health, Ageing, and Retirement in Europe [SHARE]) (9), Brazil (Brazilian Longitudinal Study of Aging [ELSI-Brazil]) (10), Mexico (Mexican Healthy Aging Study [MHAS]) (11), and India (Longitudinal Aging Study in India—Diagnostic Assessment of Dementia [LASI-DAD]) (12).
WHO Study on Global AGEing and Adult Health (SAGE) from Mexico, India, Russia, South Africa, and Ghana (13).
the Hispanic Established Populations for Epidemiologic Studies of the Elderly (Hispanic-EPESE) (14).
Baseline data were collected between 1995 and 2017 in participating studies. Study aims and design for individual studies have been published (8,10–13). The HRS-INS (HRS, ELSA, SHARE, CHARLS, ELSI-Brazil, MHAS, and LASI-DAD), and SAGE studies recruited nationally representative samples. The Hispanic-EPESE recruited community-dwelling Mexican-Americans aged 65 and older residing in the southwestern states of Arizona, California, Colorado, New Mexico, and Texas. All studies have comparable assessments of gait and other clinical characteristics—Supplementary Tables 1 and 2. All studies received approval from local institutional review boards and obtained informed consent from participants prior to enrollment. We received approval from the institutional review board of the Albert Einstein College of Medicine, New York for this analysis.
Super Mover Criteria
Super movers were defined as individuals aged 80 and older with gait speeds of ≥ 1.5 standard deviations above sex-adjusted cut scores in each participating cohort, which corresponds to gait speeds of adults 30 years younger. Super mover criteria were based on definitions for super agers—individuals aged 80 and older with superior cognitive performance (≥ 1.5 standard deviations above sex-adjusted cut scores for memory recall) (6,15). Gait speed at normal pace (participant’s preferred walking speed) over fixed distance were used to derive cohort-specific cut scores to avoid population and demographic variability (Supplementary Table 1). Also, we selected gait speed to define super mover criteria (rather than alternative measures like gait variability) due to the availability of well-established cut scores, ease of clinical interpretation, and strong potential of generalizability.
Epidemiology and Determinants of Super Mover Status
Based on expected associations with gait speed (3), and availability in different studies, we selected the following variables. The HRS-INS and SAGE studies have harmonized datasets and standardized protocols (8,13). We adopted similar variable definitions across all studies (Supplementary Table 2) (6,7,10,12–15).
Demographics and lifestyle factors: Self-reported age, sex, height, weight smoking status, sedentary behavior, and sleep quality.
Medical conditions. History of physician-diagnosed cardiovascular disease (CVD) and events (hypertension, diabetes, heart problems, and stroke) were self-reported and an average index was created. Participants were categorized as “obese” using body mass index, and established study- or country-specific cut scores (Supplementary Table 2). Depressive symptoms were assessed with Centre for Epidemiologic Studies Depression (CES-D) scale in most HRS-INS and in Hispanic-EPESE (8,14). In SHARE, depressive symptoms were assessed with EURO-D (9). In ELSI-Brazil and SAGE studies, self-reported question was used to assess depressive symptoms (10,13). Total number of medications was self-reported in each study.
Sensorimotor function. Poor hearing was self-reported, except for LASI-DAD where an objective hearing assessment was conducted (12).
Cognition and function. To compare cognitive and functional abilities of super movers, self-reported memory as well as summary indices for immediate and delayed recall tests and instrumental activities of daily living (IADLs; managing medication, money and phone calls, shopping, making hot meal, and using a map) are reported.
Mortality
Longitudinal data to assess mortality risk in super movers were available in 5 HRS-INS cohorts: HRS, ELSA, SHARE, MHAS, and CHARLS (n = 3 989). HRS reports death date obtained from decedent’s spouse, family member, or friend during an exit interview (16). Reported death dates were confirmed via Social Security Death Index and Insight databases, and linked to the National Death Index (16). ELSA obtains death year data from the National Health Service Central Data Register (17). SHARE, MHAS, and CHARLS report death month and year based on the questions answered by a proxy respondent at exit interviews.
Biological Profiles
Epigenetic and gait data, available in 262 participants aged 80 and older in the 2016 HRS venous blood substudy (18), were used to compute epigenetic clocks to study biological aging. We used second-generation epigenetic aging clocks (DNAm GrimAge and PhenoAge) (19,20), which are trained on lifestyle factors (ie, smoking) and aging correlates including biological markers (eg, C-reactive protein, creatinine, glucose, leptin, cystatin C, Alkaline phosphatase) morbidity, and mortality, thus, having greater predictive ability on health outcomes (7). AgeAccel is defined as the residual resulting from regressing predicted biological age on chronological age (difference between date of birth and assessment date) (7).
Gait Speed Trajectories
To examine gait speed trajectories over time, we chose 261 adults aged 80 and older from the Central Control of Mobility in Aging (CCMA) cohort—a Bronx-based study which had multiple annual waves of gait speed data, assessed using an instrumented walkway (21). Other participating cohorts had no or limited longitudinal gait assessments or used timed walking protocols. The aim of the CCMA study was to determine predictors of mobility in late life. Participants were recruited from population lists in Westchester County, NY. Potential participants were screened for eligibility via a telephone interview to obtain assent, and invited for in-person assessments including gait speed at normal pace assessed using an electronic GAITRite walkway (GAITRite, CIR Systems, Havertown, PA). Super movers were defined using criteria described above, based on gait speed of participants at the follow-up visit when they turned 80 years.
Statistical Analyses
Epidemiology and determinants of super mover status
In the 13 cohorts in the epidemiological analyses, we isolated 6 259 individuals aged 80 and above from 29 692 individuals aged 65 and older in the pooled sample. Those without gait data and outliers (gait speed > 250 cm/s) and those diagnosed with Alzheimer’s disease and dementia (Supplementary Table 1) were excluded. Table 1 summarizes the characteristics of participants in each study using raw sample sizes and weighted percentages.
Table 1.
Characteristics of Participants Aged 80 and Above
| HRS US |
ELSA UK |
SHARE Europe |
CHARLS China |
LASI-DAD India |
MHAS Mexico |
ELSI Brazil |
HEPESE Mexican Americans |
SAGE India |
SAGE Mexico |
SAGE Ghana |
SAGE Russia |
SAGE South Africa |
|
| n = 876 | n = 874 | n = 1 800 | n = 303 | n = 166 | n = 136 | n = 611 | n = 241 | n = 276 | n = 194 | n = 370 | n = 218 | n = 192 | |
| Demographic | |||||||||||||
| Age (y) | 84.4 (3.6) | 84.1 (3.0) | 83.6 (3.2) | 83.7 (3.1) | 83.9 (4.5) | 83.6 (4.6) | 84.1 (4.5) | 83.7 (3.2) | 83.7 (4.8) | 84.1 (3.5) | 85.3 (5.4) | 83.3 (3.3) | 84.3 (4.2) |
| Female | 527 (62) | 538 (65) | 975 (64) | 170 (62) | 74 (45) | 77 (47) | 363 (60) | 148 (61) | 127 (46) | 115 (59) | 186 (50) | 159 (73) | 116 (60) |
| Height (m) | 1.6 0.1 |
1.6 0.1 |
1.6 0.1 |
1.5 0.1 |
1.5 0.1 |
1.6 0.1 |
1.5 0.1 |
Missing data | 1.6 0.1 |
1.6 0.1 |
1.6 0.1 |
1.6 0.1 |
1.6 0.1 |
| Weight (kg) | 70.9 14.3 |
66.9 12.5 |
68.1 11.4 |
49.1 10.2 |
48.84 12.2 |
63.7 15.2 |
62.9 14.6 |
64.7 13.3 |
50.5 12.5 |
69.3 14.3 |
61.7 15.0 |
77.2 14.9 |
74.2 19.2 |
| Medical | |||||||||||||
| CVD | 0.31 (0.2) | 0.24 (0.2) | 0.26 (0.2) | 0.15 (0.2) | 0.16 (0.2) | 0.24 (0.2) | 0.24 (0.2) | 0.20 (0.2) | 0.09 (0.2) | 0.18 (0.2) | 0.04 (0.1) | 0.32 (0.2) | 0.09 (0.2) |
| Obesity | 123 (14) | 123 (18) | 188 (10) | 42 (17) | 9 (5) | 16 (8) | 164 (29) | 49 (22) | 8 (3) | 49 (26) | 19 (5) | 55 (26) | 75 (40) |
| Depression | 185 (22) | 279 (33) | 542 (34) | 87 (32) | 86 (56) | 91 (61) | 79 (14) | 21 (9) | 11 (4) | 16 (8) | 15 (4) | 6 (3) | 3 (3) |
| Poor hearing | 305 (36) | 309 (35) | 632 (38) | 226 (75) | 127 (78) | 9 (7) | 82 (12) | 49 (21) | 49 (18) | 51 (26) | 15 (4) | 70 (32) | 23 (13) |
| Medications | 2.75 (1.9) | 0.50 (0.7) | 1.38 (1.1) | 0.73 (0.9) | 0.65 (0.9) | 0.72 (0.8) | 3.35 (3.0) | 2.81 (1.7) | 1.11 (1.5) | 1.38 (1.5) | 0.71 (1.2) | 2.95 (5.0) | 1.19 (4.8) |
| Lifestyle | |||||||||||||
| Sedentary | 433 (50) | 397 (46) | 500 (31) | 92 (79) | 101 (60) | 89 (81) | 454 (77) | 49 (21) | 19 (12) | 13 (16) | 70 (31) | 23 (18) | 30 (50) |
| Poor sleep | 174 (20) | 346 (40) | 594 (37) | 119 (43) | 32 (20) | 66 (42) | 100 (16) | 21 (12) | 128 (46) | 64 (33) | 154 (42) | 127 (58) | 58 (30) |
| Smoking | 460 (53) | 560 (63) | 681 (32) | 116 (37) | 78 (47) | 53 (37) | 257 (44) | 1 515 (6) | 148 (54) | 70 (36) | 104 (28) | 35 (16) | 63 (34) |
| Cognition and function | |||||||||||||
| Subjective memory complaints | 46 (5) | 331 (37) | – | 229 (82) | 52 (34) | 76 (75) | 33 (5) | – | 60 (212) | 16 (8) | 32 (9) | 63 (29) | 27 (14) |
| Total recall | 7.65 (3.0) | 6.72 (3.2) | 5.76 (3.0) | 4.34 (2.8) | 4.43 (1.3) | 6.75 (2.5) | 3.72 (3.0) | – | 7.85 (2.9) | 7.10 (3.1) | 8.94 (3.3) | 7.98 (2.8) | 9.81 (3.7) |
| Executive function | 12.5 (2.4) | 18.8 (5.5) | 18.2 (6.2) | 3.93 (2.5) | 4.14 (2.6) | – | 2.89 (1.6) | – | 9.36 (3.2) | 11.9 (4.4) | 1.60 (1.4) | 3.16 (1.1) | 8.84 (3.3) |
| IADL difficulty | 0.50 (.98) | 0.50 (1.0) | 0.57 (1.1) | 1.29 (1.6) | 2.29 (1.9) | 0.43 (1.0) | 8.88 (4.3) | 1.28 (1.7) | – | – | – | – | – |
| Gait speed (m/s) | 0.64 (0.22) | 0.61 (0.23) | 0.60 (0.31) | 0.43 (0.18) | 0.60 (0.19) | 0.47 (0.19) | 0.57(0.25) | 0.45 (0.20) | 0.67 (0.20) | 0.55 (0.23) | 0.59 (0.24) | 0.53 (0.24) | 0.65 (0.26) |
Notes: CVD = cardiovascular disease; IADL = instrumental activities of daily living.
*The characteristics are reported with raw sample n and weighted sample %, except for SAGE cohorts which are reported with raw sample n and raw sample % (for female; medical conditions except for number of medication; and lifestyle factors). We present the raw sample n and weighted subsample n to show the number of observations the estimates are based on, the percentages are the weighted proportion estimates (the population estimates of the proportions).
†Values are reported with M (SD) or n (%).
‡Note that in each study the full sample did not have data for all the variables.
Logistic regression (binary variables) and linear regression (continuous variables) were used to determine associations between selected factors with super mover status in each study using Stata survey data analysis package (StataCorp LLC, College Station, TX). Models were adjusted for age and sex, and associations reported as odds ratios (OR) for binary variables or estimates of difference (ie, beta coefficients) and 95% confidence intervals (CI). In all studies, poststratification sample weights that account for the variations in the participant selection were applied to models as suggested by parent studies. Second, for each factor that was associated with super mover status, OR (or coefficient estimates) and standard errors were extracted, and meta-analysis was performed using Stata meta suite (https://www.stata.com/stata16/meta-analysis/) to obtain overall associations of the selected factors with super mover status—using the Cochrane Q_b statistic.
Mortality
To determine whether super movers have lower mortality, we used Cox proportional hazard models to compute adjusted hazard ratios (HR) with 95% CI. Person-time variables were obtained by calculating time in days between baseline assessment date and death date or final assessment date if the participant remained alive over follow-up. Proportionality of the models was examined graphically and statistically and found to be adequately met.
Biology
Linear regression models were used to examine differences in the AgeAccel measures between super movers and controls, adjusting for age and sex. Survey weights from the 2016 Venous Blood Study were additionally applied.
Gait speed trajectories
Linear mixed effect models with a change point (centered at age 80) were used to visualize the trajectories of gait speed decline before and after the age of 80 of both super mover and nonsuper movers (controls).
Results
Epidemiology
The weighted prevalence of super movers among adults 80 and older in the 13 cohorts across 24 countries varied from 4.9% in ELSI-Brazil to 11.1% in SAGE-South Africa, and only 19% of them met criteria for super agers in the pooled sample. Meta-analytic prevalence across all 13 cohorts was 7.3%—see Figure 1. Prevalence of super movers stratified by sex is in Supplementary Table 3.
Figure 1.
Forest plot of prevalence of super movers. Abbreviations: Health and Retirement Study (HRS); English Longitudinal Study of Ageing (ELSA), Chinese Health and Retirement Longitudinal Study (CHARLS), Survey of Health, Ageing, and Retirement in Europe (SHARE), Brazilian Longitudinal Study of Aging (ELSI-Brazil), Mexican Healthy Aging Study (MHAS), Longitudinal Aging Study in India (LASI), WHO Study on Global AGEing and Adult Health (SAGE), and the Hispanic Established Populations for Epidemiologic Studies of the Elderly (Hispanic-EPESE).
Table 2 provides the results of meta-analysis of associations of clinical factors with super mover status, adjusted for age and sex. All factors (except for obesity) were significantly (p < .01) related to super mover status. Super movers (OR 0.96, 95% CI: 0.63–1.28) were less likely to be female. Super movers had lower CVD and vascular risk factor burden (difference −0.08, 95% CI: −0.11 to −0.05), depression (effect size 0.28, 95% CI: 0.09–0.47), and poor hearing (OR 0.46, 95% CI: 0.23–1.3) than age peers. They used fewer medications (difference −0.01, 95% CI: −0.02 to −0.004). Super movers were less likely to be sedentary (OR 0.21, 95% CI: 0.14–0.28), report poor sleep (OR 0.48, 95% CI: 0.32–0.65), and smoke (OR 0.77, 95% CI: 0.52–1.0) than controls.
Table 2.
Associations Between Individual Factors and Supermovers in the Meta-analysis
| Estimate (95% CI) | Test of Homogeneity: Q | p Value | |
| Female | 0.962 (0.637, 1.288) | 20.21 | 0.0000 |
| CVD | −0.078 (−0.111, −0.045) | 5.31 | 0.0000 |
| Obesity | 0.000 (−0.000, 0.000) | 35.48 | 0.3237 |
| Sedentariness | 0.208 (0.136, 0.280) | 9.62 | 0.0000 |
| Depressive symptoms | 0.282 (0.094, 0.471) | 56.84 | 0.0033 |
| Poor sleep | 0.482 (0.318, 0.646) | 12.02 | 0.0000 |
| Poor hearing | 0.463 (0.230, 0.696) | 54.78 | 0.0001 |
| Subjective memory complaints | 0.305 (0.092, 0.519) | 28.76 | 0.0014 |
| Medication use | −0.010 (−0.015, −0.004) | 30.45 | 0.0008 |
| Total recall | 0.008 (0.004, 0.011) | 17.01 | 0.0000 |
| IADL | −0.019 (−0.028, −0.010) | 40.60 | 0.0000 |
| Smoke | 0.765 (0.515, 1.015) | 11.91 | 0.0000 |
Notes: CVD = cardiovascular disease; IADL = instrumental activities of daily living. The estimates indicate odds ratios for binary variables and the estimated difference between super movers versus nonsuper movers for continuous variables.
Super movers were less likely to report subjective memory complaints (OR 0.31, 95% CI: 0.08–0.54) and had better total memory recall (difference 0.01, 95% CI: 0.004–0.01) than controls. Super movers had less difficulty in IADLs (difference −0.02, 95% CI: −0.03 to −0.01).
Mortality
The mortality analysis included 3 989 participants from 5 cohorts (HRS, ELSA, SHARE, CHARLS, and MHAS). Median survival time for 358 super movers and 3 631 nonsuper movers was 6.5 and 5.1 years, respectively. Over follow-up period (ranging from 4.4 years in CHARLS to 15.1 years in HRS), there were 537 (13%) deaths (155 super movers and 382 nonsuper movers). Figure 2 depicts mortality risk by super mover status. Super movers had lower mortality in all cohorts, ranging from HR 0.14 (95% CI: 0.02–0.89) in MHAS to HR 0.72 (95% CI: 0.45–0.99) in SHARE. Super mover status at baseline predicted mortality (HR 0.38, 95% CI: 0.09–0.66) in the pooled sample—Figure 2, and Supplementary Figure 1 presents pooled sample analysis.
Figure 2.
Kaplan–Meier curves for probability of mortality by super mover status in the U.S. Health and Retirement Study.
Biology
We identified 229 participants aged 80 and older with biological aging measures and without dementia in the 2016 HRS Venous Blood Study sample—20 (8.7%) super movers. Super movers had younger biological age as evidenced by lower GrimAge AgeAccel (difference (standard error) −0.380 (0.184), p = .040) and PhenoAge Accel (difference (standard error) −0.528 (0.247), p = .034) values compared to nonsuper movers, adjusted for age and sex. When survey weights were applied, associations of GrimAge AgeAccel (difference (standard error) −0.323 (0.182), p = .077) and PhenoAge Accel (difference (standard error) −0.491 (0.249), p = .049) with super mover status remained but weakened.
Gait Speed Trajectories
In the CCMA cohort, we identified 22 (8%) super movers out of 261 participants aged 80 and older. Gait speed trajectories were assessed using piecewise regression, with breakpoint at age 80 (Figure 3). Both super movers and nonsuper movers had similar trajectories in gait speed decline, although super movers maintained faster gait speed than nonsuper movers from their seventh to tenth decades.
Figure 3.
Trajectories of decline in gait speed in super movers versus nonsuper movers in the Central Control of Mobility in Aging cohort.
Discussion
In this inaugural report, we introduce the concept of super movers, a novel exceptional aging phenotype. A super mover is an individual 80 years or older with walking speed comparable to an average person 3 decades younger. Persons meeting super mover criteria tend to be male and have better cognitive status than age peers. Super movers had lower prevalence of CVD and risk factors, depressive symptoms, and poor hearing. They used fewer medications and had healthier lifestyle characteristics than controls. Super movers had longer survival rates, younger biological age, and superior gait speed throughout the follow-ups in the CCMA study.
The health advantages of super movers may result from both environmental and genetic factors. A New Zealand-based birth cohort that tracked individuals to age 45 reported that slow gait speed at midlife already reflected signs of accelerated biological aging assessed by a panel of biomarkers and facial aging (22). The super movers’ younger biological age supports presence of an advantageous biology, which may result not only from genetic predisposition but also from healthy lifestyle practices. For instance, super movers were less likely to be sedentary, report poor sleep, or smoke, which may influence biological aging (23).
Health advantages of super movers are supported by the mortality analysis in 5 cohorts. Super movers had a 62% reduced hazard of mortality compared to age peers in the pooled sample. Our findings are consistent with reports of gait speed being associated with survival in older populations worldwide (2). The lower mortality may be due to the healthier lifestyle of super movers compared to age peers. Siblings of centenarians were more likely to survive to exceptionally old age in the New England Centenarian Study (24). Similar findings were reported in first degree relatives of extremely long-lived individuals in Iceland (25).
This initial report on the new aging phenotype has several limitations. Comparisons for super movers were made with age peers, but these controls are also exceptional in terms of surviving into their ninth decade. Despite this, clinical, lifestyle, and biological differences did distinguish super movers, confirming their unique status. More studies are needed to delineate super mover biology. All participating cohorts had comparable gait protocols. Gait speed in older adults can vary across different cohorts and countries due to differences in factors such as height, sex, race and ethnicity, education, and socioeconomic status (26,27). Hence, a universal single gait speed cut score will introduce heterogeneity between cohorts, especially in underserved minorities. For example, applying a widely used gait speed threshold of > 1.0 m/s in the US HRS cohort defines fast gait in 7.7% of White adults, but only 3.8% of African American and 2.7% of Hispanic adults, though most in all ethnic groups were ambulatory and independent. Gait performance is commonly characterized by speed, which was used to define Super Movers to improve generalizability and facilitate cross-validations across diverse settings. However, other factors, such as variability in gait speed, may offer deeper insights into mobility performance in super movers, and should be explored in future studies.
While we examined many clinical variables, we did not examine all possible variables due to limited data availability or lack of standardized definitions. For instance, education, which is associated with better cognition, was not included due to inconsistent reporting across cohorts or due to issues of harmonizing education reported using different metrics, as well as differences in quality of education across countries. Future studies need to conduct more comprehensive examination of other clinical variables.
Super movers represent a novel exceptional aging phenotype characterized by distinct biological, clinical, and behavioral profiles. Whether health advantages observed in super movers stem from healthier lifestyles and reduced disease burden or if there is also a genetic predisposition contributing to this status is unclear. Exploring the biological foundations of better health, cognition, and longevity in super movers could yield valuable insights into the protective mechanisms that facilitate healthy longevity. Notably, there was less than 20% overlap between the super mover and super agers phenotypes suggesting that examining these distinct profiles may reveal complementary strategies inform effective interventions aimed at promoting successful aging for the general population (28–30).
Supplementary Material
Contributor Information
Joe Verghese, Department of Neurology, Renaissance School of Medicine, Stony Brook, New York, USA.
Kelly Cotton, Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA.
Sanish Sathyan, Department of Neurology, Renaissance School of Medicine, Stony Brook, New York, USA.
Emmeline Ayers, Department of Neurology, Renaissance School of Medicine, Stony Brook, New York, USA.
Jeannette R Mahoney, Department of Neurology, Renaissance School of Medicine, Stony Brook, New York, USA.
Pierfilippo De Sanctis, Department of Neurology, Albert Einstein College of Medicine, Bronx, New York, USA.
Cuiling Wang, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA.
Ying Jin, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA.
Helena M Blumen, Department of Neurology, Renaissance School of Medicine, Stony Brook, New York, USA.
Oshadi Jayakody, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.
Lewis A Lipsitz, (Medical Sciences Section).
Funding
This project is funded by National Institutes of Health, USA grant R01 AG030153 (PI: Joe Verghese, MD).
The Gateway to Global Aging dataset was funded by the National Institutes of Health, USA grants RC2 AG036619, R03 AG043052, and R24 AG048024.
The Central Control of Mobility in Aging study was funded by the National Institutes of Health, USA grants R01AG036921 and R01AG044007.
The Rush Memory and Aging project study is funded by National Institutes of Health, USA grants P30AG10161, R01AG15819, and R01AG17917 (PI: David Bennett, MD).
Conflict of Interest
None.
Data Availability
This study used the data from the Program on Global Aging, Health, and Policy prog.g2aging.org. The Center for Economic and Social Research (CESR) cesr.usc.edu.
Author Contributions
Conceptualization: J.V., S.S., E.A., J.R.M., P.D., H.M.B.
Methodology: J.V., K.C., S.S., E.A., C.W., Y.J., O.J.
Investigation: J.V., Y.J., O.J.
Visualization: K.C., Y.J., C.W., O.J.
Funding acquisition: J.V., S.S., E.A., J.R.M., P.D., H.M.B.
Project administration: J.V., E.A.
Supervision: J.V., E.A., O.J.
Writing—original draft: J.V., O.J.
Writing—review & editing: K.C., S.S., E.A., J.R.M., P.D., C.W., Y.J., H.M.B.
References
- 1. Ayers E, Verghese J.. Locomotion, cognition and influences of nutrition in ageing. Proc Nutr Soc. 2014;73(2):302–308. https://doi.org/ 10.1017/S0029665113003716 [DOI] [PubMed] [Google Scholar]
- 2. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305(1):50–58. https://doi.org/ 10.1001/jama.2010.1923 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Oh-Park M, Holtzer R, Xue X, Verghese J.. Conventional and robust quantitative gait norms in community-dwelling older adults. J Am Geriatr Soc. 2010;58(8):1512–1518. https://doi.org/ 10.1111/j.1532-5415.2010.02962.x [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Milman S, Barzilai N.. Discovering biological mechanisms of exceptional human health span and life span. Cold Spring Harb Perspect Med. 2023;13(9):a041204. https://doi.org/ 10.1101/cshperspect.a041204 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Qiu C, Fratiglioni L.. Aging without dementia is achievable: current evidence from epidemiological research. J Alzheimers Dis. 2018;62(3):933–942. https://doi.org/ 10.3233/JAD-171037 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. de Godoy LL, Alves C, Saavedra JSM, et al. Understanding brain resilience in superagers: a systematic review. Neuroradiology. 2021;63(5):663–683. https://doi.org/ 10.1007/s00234-020-02562-1 [DOI] [PubMed] [Google Scholar]
- 7. Sathyan S, Ayers E, Adhikari D, et al. Biological age acceleration and motoric cognitive risk syndrome. Ann Neurol. 2023;93(6):1187–1197. https://doi.org/ 10.1002/ana.26624 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Sonnega A, Faul JD, Ofstedal MB, Langa KM, Phillips JW, Weir DR.. Cohort Profile: the Health and Retirement Study (HRS). Int J Epidemiol. 2014;43(2):576–585. https://doi.org/ 10.1093/ije/dyu067 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Börsch-Supan A, Brandt M, Hunkler C, et al. ; SHARE Central Coordination Team. Data Resource Profile: the Survey of Health, Ageing and Retirement in Europe (SHARE). Int J Epidemiol. 2013;42(4):992–1001. https://doi.org/ 10.1093/ije/dyt088 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Lima-Costa MF, de Andrade FB, de SouzaPRB, Jr, et al. The Brazilian Longitudinal Study of Aging (ELSI-Brazil): objectives and design. Am J Epidemiol. 2018;187(7):1345–1353. https://doi.org/ 10.1093/aje/kwx387 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Kammar-García A, Ramírez-Aldana R, Roa-Rojas P, et al. Association of loneliness and social isolation with all-cause mortality among older Mexican adults in the Mexican health and aging study: a retrospective observational study. BMC Geriatr. 2023;23(1):45. https://doi.org/ 10.1186/s12877-023-03750-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Lee J, Khobragade PY, Banerjee J, et al. Design and Methodology of the Longitudinal Aging Study in India-Diagnostic Assessment of Dementia (LASI-DAD). J Am Geriatr Soc. 2020;68(suppl 3):S5–S10. https://doi.org/ 10.1111/jgs.16737 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13. Kowal P, Chatterji S, Naidoo N, et al. ; SAGE Collaborators. Data resource profile: the World Health Organization Study on global AGEing and adult health (SAGE). Int J Epidemiol. 2012;41(6):1639–1649. https://doi.org/ 10.1093/ije/dys210 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14. Guralnik JM, Ferrucci L, Pieper CF, et al. Lower extremity function and subsequent disability: consistency across studies, predictive models, and value of gait speed alone compared with the short physical performance battery. J Gerontol A Biol Sci Med Sci. 2000;55(4):M221–M231. https://doi.org/ 10.1093/gerona/55.4.m221 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Garo-Pascual M, Zhang L, Valentí-Soler M, Strange BA.. Superagers resist typical age-related white matter structural changes. J Neurosci. 2024;44(25):e2059232024. https://doi.org/ 10.1523/JNEUROSCI.2059-23.2024 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Monnat SM, Elo IT.. Enhancing the Utility of the Health and Retirement Study (HRS) to identify drivers of rising mortality rates in the United States. Forum Health Econ Policy. 2022;25(1-2):57–84. https://doi.org/ 10.1515/fhep-2021-0058 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Steptoe A, Shankar A, Demakakos P, Wardle J.. Social isolation, loneliness, and all-cause mortality in older men and women. Proc Natl Acad Sci U S A. 2013;110(15):5797–5801. https://doi.org/ 10.1073/pnas.1219686110 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18. Crimmins EM, Thyagarajan B, Levine ME, Weir DR, Faul J.. Associations of age, sex, race/ethnicity, and education with 13 epigenetic clocks in a nationally representative U.S. sample: the Health and Retirement Study. J Gerontol A Biol Sci Med Sci. 2021;76(6):1117–1123. https://doi.org/ 10.1093/gerona/glab016 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Lu AT, Quach A, Wilson JG, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging (Albany NY). 2019;11(2):303–327. https://doi.org/ 10.18632/aging.101684 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Levine ME, Lu AT, Quach A, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY). 2018;10(4):573–591. https://doi.org/ 10.18632/aging.101414 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Verghese J, Annweiler C, Ayers E, et al. Motoric cognitive risk syndrome: multicountry prevalence and dementia risk. Neurology. 2014;83(8):718–726. https://doi.org/ 10.1212/WNL.0000000000000717 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Rasmussen LJH, Caspi A, Ambler A, et al. Association of neurocognitive and physical function with gait speed in midlife. JAMA Netw Open. 2019;2(10):e1913123. https://doi.org/ 10.1001/jamanetworkopen.2019.13123 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Wu D, Qu C, Huang P, et al. Better Life’s Essential 8 contributes to slowing the biological aging process: a cross-sectional study based on NHANES 2007–2010 data. Front Public Health. 2024;12:1295477. https://doi.org/ 10.3389/fpubh.2024.1295477 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. Perls TT, Wilmoth J, Levenson R, et al. Life-long sustained mortality advantage of siblings of centenarians. Proc Natl Acad Sci U S A. 2002;99(12):8442–8447. https://doi.org/ 10.1073/pnas.122587599 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Gudmundsson H, Gudbjartsson DF, Frigge M, Gulcher JR, Stefánsson K.. Inheritance of human longevity in Iceland. Eur J Hum Genet. 2000;8(10):743–749. https://doi.org/ 10.1038/sj.ejhg.5200527 [DOI] [PubMed] [Google Scholar]
- 26. Boulifard DA, Ayers E, Verghese J.. Home-based gait speed assessment: normative data and racial/ethnic correlates among older adults. J Am Med Dir Assoc. 2019;20(10):1224–1229. https://doi.org/ 10.1016/j.jamda.2019.06.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Capistrant BD, Glymour MM, Berkman LF.. Assessing mobility difficulties for cross-national comparisons: results from the World Health Organization Study on Global AGEing and Adult Health. J Am Geriatr Soc. 2014;62(2):329–335. https://doi.org/ 10.1111/jgs.12633 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28. Wilson RS, Arnold SE, Schneider JA, Tang Y, Bennett DA.. The relationship between cerebral Alzheimer’s disease pathology and odour identification in old age. J Neurol Neurosurg Psychiatry. 2007;78(1):30–35. https://doi.org/ 10.1136/jnnp.2006.099721 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Oveisgharan S, Wang T, Barnes LL, Schneider JA, Bennett DA, Buchman AS.. The time course of motor and cognitive decline in older adults and their associations with brain pathologies: a multicohort study. Lancet Healthy Longev. 2024;5(5):e336–e345. https://doi.org/ 10.1016/S2666-7568(24)00033-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30. Dominguez EN, Corrada MM, Kawas CH, Stark CEL.. Resilience to AD pathology in top cognitive performers. Front Aging Neurosci. 2024;16:1428695. https://doi.org/ 10.3389/fnagi.2024.1428695 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
This study used the data from the Program on Global Aging, Health, and Policy prog.g2aging.org. The Center for Economic and Social Research (CESR) cesr.usc.edu.



